Phase I
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
EIP Pharma, based in Cambridge, Massachusetts, closed on a $20.5 million Series B financing. The round was led by Access Industries.
Shares of MEI Pharma, Inc. are up nearly 9 percent this morning after the company snagged $75 million in a private placement that was led by Vivo Capital and CAM Capital. The funds will be used to treat adults with relapsed or refractory follicular lymphoma with a P13K inhibitor.
Medigene and bluebird bio announced they are expanding a strategic research and development collaboration inked in September 2016.
Shares of Utah-based Lipocine, Inc. are down more than 41 percent in premarket trading after the company announced it received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its testosterone replacement therapy product.
Akili Interactive, headquartered in Boston, closed a $55 million Series C financing. Akili is a prescription digital medicine company. Its goal is to treat certain disorders via high-quality video games.
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
PRESS RELEASES